Background
Methods
PRO-KIND JDM working group and expert panel
Consensus conference
Results
Expert panel
Diagnosis and case definition
Statements | Consensus |
---|---|
Diagnosis | 100% |
For the diagnosis of juvenile dermatomyositis, the following findings should be present prior to age 18 years: • Typical skin finding (heliotrope and/or Gottron-sign/−papules) Additional criteria: • Symmetric proximal muscle weakness and/or myalgia • Increased muscle-related enzymes (creatine kinase, glutamate oxaloacetate transaminase, lactate dehydrogenase and/or aldolase) • Typical findings on muscle biopsy • Typical findings on magnetic resonance imaging Other possible etiologies should be excluded. Probable JDM: Skin findings and at least 2 additional criteria Definite JDM: Skin findings and at least 3 additional criteria | |
Case definition | 92% |
The treatment strategies discussed below apply to patients with active moderately severe or severe juvenile dermatomyositis. Patients with severe juvenile dermatomyositis fulfill at least one of the following characteristics and none of these characteristics is present in patients with moderate JDM: • Age < 1 year • Requirement for intensive care therapy • Marked disability as measured by being bedridden, childhood myositis assessment scale (CMAS) < 15 or manual muscle testing (MMT)8 < 30 • Relevant pulmonary disease • Myocarditis • Vasculitis with organ involvement (gastrointestinal tract, kidney, lungs or central nervous system) • Aspiration or marked dysphagia • Severe cutaneous ulceration • Significant calcinosis | |
Diagnostic work-up | 100% |
Obtaining the following parameters may be useful in case of probable or definite JDM: • Laboratory tests: o Enzymes (creatine kinase, glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, lactate dehydrogenase, aldolase) o Complete blood count with differential count o Routine serum chemistry panel o Inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) o Antinuclear antibody (ANA) o In case of positive ANA: anti-ds-DNA, anti-PM-Scl, Sm antibodies, anti-SS-A, anti-SS-B and anti-U1RNP antibodies o Extended myositis-blot/myositis-specific antibody (incl. Anti-synthetase, anti-MDA5, anti-Mi-2, anti-NXP-2, anti-SRP, anti-TIF-1-γ antibodies) o Immunoglobulin (Ig)G, IgA, IgM o Complement (CH50) o Von Willebrand factor-antigen o Troponin o TSH o Immunization status o Urinalysis o Stool for occult blood • Further testing: o Electrocardiography o Echocardiography o Magnetic resonance imaging (incl. Short tau inversion recovery or equivalent sequences) o Chest X-ray o Abdominal ultrasound o Muscle ultrasound o Muscle biopsy o Bodyplethysmography with CO-diffusion capacity o Capillary microscopy |
Disease monitoring
Statement | Consensus |
---|---|
Disease monitoring tools | 100% |
In order to monitor disease activity and disease damage over time, the regular measurement of the following parameters may be useful (initially every 6 weeks, later every 3 months): • Length, weight, blood pressure • Physician global assessment of disease activity (visual analog scale 0–10) • Parent/Patient global assessment of disease activity (visual analog 0–10) • Manual muscle testing (MMT)8 and/or Childhood Myositis Assessment Scale (CMAS) • Childhood Health Assessment Questionnaire (CHAQ) • A validated Quality of life instrument • Muscle enzymes • Extramuscular disease activity, e.g. via Disease Activity Score, Myositis Disease Activity Assessment Tool or Visual Analog Scale • Myositis damage index (annually) |
Treatment strategy and treatment targets
Statements | Consensus |
---|---|
Treatment targets | 100% |
The overall goal is clinical inactive disease within 1 year after initiation of therapy, ideally under a glucocorticoid-free treatment regimen. Under some circumstances, low-dose glucocorticoids or intermittent intravenous methylprednisolone pulse therapy may be acceptable. The following interim improvementa is targeted: • At least a moderate improvement within 6 weeks after initiation or substantial change in therapy. • At least a major improvement within 3 months after initiation or substantial change in therapy. | |
General treatment strategy | 92% |
The consensus treatment strategies for JDM serve to harmonize existing therapies in clinical practice. The treatment strategy generally consists of a treat-to-target strategy, i.e. therapies are modified according to reaching or failing previously established targets. In addition, there is a more intensive first (induction) treatment phase (6–8 weeks) and a less intensive subsequent (maintenance) phase. Components of the initial therapy include glucocorticoids and glucocorticoid-sparing DMARDs. |
Specific therapies for juvenile dermatomyositis
Supportive therapies
Statements | Consensus |
---|---|
Supportive therapy | 100% |
Early and intensive physical therapy is essential in order to avoid contractures and improve/maintain muscle strength, even during active myositis. Participation in sports is desirable after individual counseling. Effective sun protection is essential, incl. textile protection and sunscreen. The following treatments may be considered individually: • Supplementation of vitamin D, e.g. depending on 25-OH vitamin D level, glucocorticoid treatment and/or bone mineral density • Supplementation of calcium, e.g. in case of insufficient intake • Hydroxychloroquin | |
Initial glucocorticoid therapy | 92% |
The principal glucocorticoid strategy options include • Intermittent intravenous methylprednisolone pulse (IVMP) therapy + moderate-to-high-dose daily glucocorticoids (prednisone equivalent 0.5–2 mg/kg [max. 80 mg] daily) • Intermittent IVMP therapy + lower-to-moderate dose daily glucocorticoids (prednisone equivalent 0.2–0.5 mg/kg daily) • High-dose daily glucocorticoid therapy (2 mg/kg [max. 60–80 mg] daily) +/− initial single IVMP pulse | |
Glucocorticoid tapering | 92% |
The following landmarks may be applied when tapering glucocorticoids, assuming an adequate treatment response (i.e. treatment targets are reached): • IVMP o 20–30 mg/kg (max. 1000 mg) daily × 3 days o At 2 and 4 weeks, subsequently every 4–6 weeks × 6–12 months • High-dose daily glucocorticoids (prednisone or prednisolone) o 2 mg/kg (max. 60–80 mg) × 1 month, then start taper o 50% of initial dose at 2 months, 25% at 4 months, 12.5% at 6 months, discontinue at 12 months • Moderate-dose daily glucocorticoids (0.5–2 mg/kg daily, < 60 mg daily) o Stop within 12 months • Lower-dose daily glucocorticoids (< 0.5 mg/kg daily) o Stop within 12 months | |
Glucocorticoid-sparing therapies | 100% |
The following glucocorticoid-sparing therapies are used in the initial treatment: • Methotrexate (MTX) 15–20 mg/m2 (max. 30 mg) once weekly (s.c. preferred) • MTX 15–20 mg/m2 (max. 30 mg) once weekly (s.c. preferred) + intravenous immune globulins (IVIG) (especially in case of severe juvenile dermatomyositis) In case of MTX intolerance, MTX can be replaced by azathioprin (AZA), cyclosporin A (CSA) or mycophenolate mofetil (MMF). | |
Refractory disease | 92% |
In case of not reaching predefined targets (Table 3) or disease flare, a change in therapy is required. In this situation, current therapies should be intensified, exchanged and/or another therapy added. Further treatment should be discussed individually with experts. The following agents are generally used: AZA, calcineurin inhibitors, cyclophosphamide, IVIG, MMFmycophenolate mofetil, rituximab, tumor necrosis factor inhibitors |